Background: Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD.
A nthracyclines are a class of highly effective chemotherapeutic agents incorporated into more than half of all childhood cancer treatments (1, 2) . However, they are associated with dose-dependent cardiotoxicity, which manifests along a continuum from asymptomatic left ventricular dysfunction (ALVD) to clinical heart failure (HF) (1) . Five-year survival after HF diagnosis is generally poor (3) (4) (5) .
The Children's Oncology Group Long-Term Followup Guidelines (COG guidelines) (6) recommend lifelong serial echocardiographic screening for survivors of childhood cancer to identify anthracycline-related ALVD and to delay the onset of HF with ALVD treatment (for example, angiotensin-converting enzyme [ACE] inhibitors or ␤-blockers) (7) . The guidelines recommend screening frequencies of 1 to 5 years, depending on 12 risk profiles defined by lifetime anthracycline dose, age at cancer diagnosis, and history of chest irradiation (8) . These frequencies take into account the evidence for clinical and demographic modifiers of the dose-dependent risk for ALVD or HF but are essentially consensus-based.
Excessive screening wastes scarce financial resources, whereas inadequate screening delays ALVD treatment. The purpose of this study was to determine the efficacy and cost-effectiveness of the COG guidelines and to explore alternative screening schedules that might be more cost-effective.
The CCSS data included information on 4635 anthracycline-exposed survivors of childhood cancer treated from 1970 to 1986 in the United States and Canada and followed to 31 December 2002 (Appendix 1). Male patients made up 54.5% of that study sample, the median age at cancer diagnosis was 7 years (range, 0 to 20 years), the median cumulative anthracycline dose was 292.8 mg/m 2 , 22% of patients received chest irradiation, and the median duration of follow-up after cancer diagnosis was 20 years (10, 11) .
Model Structure
The model comprised 4 health states (no ALVD, ALVD, HF, death) (Appendix Figure 1 , available at www .annals.org), which closely resembled the American Heart Association and American College of Cardiology definitions of HF (7): stage A (no ALVD), stage B (ALVD), and stage C/D (HF). Individuals were ALVD-free at the start of simulation. They underwent lifetime echocardiographic screening according to the COG guidelines with 100% adherence. The model used a 1-year cycle length.
The correct diagnosis of ALVD depended on the sensitivity and specificity of the screening echocardiography. After echocardiographic screening, individuals with ALVD had true-positive or false-negative results; those without ALVD had false-positive or true-negative results. Truepositive patients underwent cardiac magnetic resonance imaging (MRI) to confirm ALVD, followed by treatment (ACE inhibitor and ␤-blocker) with 76% adherence (12). Those in whom HF developed received an ACE inhibitor and a ␤-blocker. They could remain stable (no disease progression), be hospitalized for HF, or die of HF or of noncardiac causes. False-positive patients underwent cardiac MRI to rule out ALVD and continued with screening per the COG guidelines, as did the false-and true-negative patients. Survivors in any health state could die of non-HF causes.
Model Inputs Echocardiography Performance Characteristics
Medical literature review showed the ranges of sensitivity and specificity for echocardiography to be 75% to 94% and 90% to 100%, respectively, with radionuclide angiography as the reference standard ( Table 1 and Appendix 1) (13) (14) (15) (16) (17) (18) . Thus, we used conservative values of 75% for sensitivity and 90% for specificity.
Efficacy of ALVD Treatment
Treatment for ALVD was assumed to reduce the annual HF incidence by 30% ( Table 1 and Appendix 1) (12, 19, 20) .
Incidence of HF and ALVD
The annual incidence of HF from 5 to 30 years after cancer diagnosis was synthesized from published studies ( Table 1 ; Appendix 1; and Appendix Figures 2 and 3, available at www.annals.org) (3, (21) (22) (23) (24) (25) (26) (27) (28) . Given sparse data, HF incidence beyond 20 years after diagnosis was held at the 20-year rate but incorporated the age-and sex-specific
Context
Guidelines recommend that childhood cancer survivors undergo periodic, lifetime screening echocardiography every 1 to 5 years to detect asymptomatic left ventricular dysfunction.
Contribution
Mathematical models were used to compare lifetime costs, quality-adjusted life-years, and total risks for heart failure for different screening intervals versus no screening of a hypothetical population of 5-year childhood cancer survivors. Screening frequencies differed according to 12 risk profiles based on age at diagnosis, total anthracycline dose, and history of chest irradiation.
Caution
Many model parameters were derived from studies involving adults with heart failure without a history of cancer.
Implication
Although routine echocardiography may reduce incidence of heart failure, less frequent screenings every 1 to 5 years are more cost-effective and maintain most of the health benefits.
-The Editors
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Cost-Effectiveness of Children's Oncology Group Echocardiographic Screening Guidelines HF incidence of the general population (29). The annual ALVD incidence was assumed to be 3 times that of HF (see Appendix 1 for rationale). The cumulative incidences of ALVD and lifetime mortality from HF are shown in Appendix Table 2 (available at www.annals.org).
Annual Mortality
Non-HF mortality was estimated from 4635 anthracycline-exposed CCSS participants (30) up to age 30 years for age at cancer diagnosis younger than 5 years and up to age 40 years for cancer diagnosis at age 5 years or older. Mortality rates beyond these ages were estimated from the age-and sex-appropriate U.S. general population by applying the multiplicative assumption and the relative risks estimated at ages 30 and 40 years ( Table 1 ; Appendix 1; and Appendix Figure 4 , available at www.annals.org). The annual HF mortality was derived from data in children (approximated by the rate of HF death or progression to heart transplantation) (31) and adults with HF (32, 33) .
Utilities
We used health state values estimated from healthy men and women for the 4 heart disease classifications of the New York Heart Association for our 3 alive health states (34) . For ages 26 to 45 and 46 to 65 years, sexspecific means were used. For ages younger than 26 or older than 65 years, linearly extrapolated values at 15 and 85 years, respectively, were used. To account for adverse effects of ALVD treatment (35) , the decrement in ALVD utility relative to no ALVD was increased by 25% in 20% of ALVD patients (36) ( Table 1 and Appendix 1).
Costs
Costs ( Table 2 and Appendix 1) were adjusted to 2010 U.S. dollars by using the medical portion of the Consumer Price Index of the U.S. Bureau of Labor Statistics. Costs of 2-dimensional screening echocardiography and cardiac MRI were obtained from the 2010 Medicare Physician Fee Schedule (38). We used the average wholesale price for ACE inhibitors and ␤-blockers (39). Health care costs included age-dependent general health care (40) , hospitalization leading to non-HF death (41) , hospitalization for HF ending in discharge or death (41) , and outpatient HF management (38). Patient time was valued at $143 per day based on 2010 U.S. median annual earnings (42) .
Sensitivity Analyses
One-way sensitivity analyses were conducted for ALVD treatment efficacy and duration of efficacy, sensitivity and specificity of echocardiography, medication adherence rate, the cumulative incidence of HF at 20 years after cancer diagnosis, utilities for HF, discount rates, and echocardiographic screening cost (Tables 1 and 2) . Two-way sensitivity analyses were also conducted for echocardiographic sensitivity and specificity and ALVD treatment efficacy. Cohort values were calculated by using weighted averages of QALYs and cost calculated for the risk groups using their prevalence as weights.
Identifying a Cost-Effective Screening Strategy
Health care cost and QALYs for screening frequencies of 1 to 5 years were calculated for each risk profile. The 
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Cost-Effectiveness of Children's Oncology Group Echocardiographic Screening Guidelines frequencies were ordered by QALYs. The incremental cost per QALY gained by increasing the screening frequency to the next higher level was calculated (9) . Frequencies providing fewer QALYs for equal or higher cost than other frequencies or frequencies gaining fewer QALYs for equal or higher cost than a combination of 2 other frequencies were eliminated (9, 43) . The remaining frequency with the highest QALY gained at less than $100 000 was considered the most cost-effective.
Role of the Funding Source
The study was supported in part by the Lance Armstrong Foundation and the National Cancer Institute. The funding sources had no role in the design or conduct of the study or the decision to publish the study findings.
RESULTS
Model Validation
Model validation procedures are detailed in Appendix 2 (available at www.annals.org). External model validity was assessed by comparing model-based estimates of the cumulative incidence of HF at 20 years after cancer diagnosis with estimates reported in 4 large cohort studies (21) (22) (23) 28) . Because the cohort characteristics were reported in aggregates, we identified specific risk profiles in the guidelines that could correspond to the study data. The range of cumulative incidence calculated for these risk profiles (0.5% to 5.8%) overlapped the estimates or the 95% confidence limits reported by the 4 studies (2% to 7.9%) (Appendix Table 3 , available at www.annals.org).
Base Case
Within each category of age at cancer diagnosis, life expectancy and QALYs gained from screening increased with higher anthracycline dose. The reduction in HF risk was highest in the first 2 decades after cancer diagnosis and decreased thereafter. The largest reduction in HF risk occurred for screening performed soon after cancer diagnosis ( Table 3) .
Following the COG guidelines for life instead of no screening increased the average cohort life expectancy from 56.8 to 57.3 years; delayed HF onset by an average of 1.5 years; increased the average QALY by 0.13; and decreased the cumulative incidence ("risk") of HF by 23%, 18%, and 12% at 20, 30, and 50 years after cancer diagnosis, respectively. Across risk profiles 2 to 12, the average gain in life expectancy ranged from 2.6 to 11.3 months; the gain in QALYs ranged from 0.02 to 0.25; and the reduction in HF risk at 20, 30, and 50 years after cancer diagnosis ranged from 12.3% to 24.7%, 12.1% to 19.6%, and 9.2% to AC ϭ anthracycline; COG ϭ Children's Oncology Group; Dx ϭ diagnosis; HF ϭ heart failure; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year; RT ϭ irradiation. * Excludes risk profile 1 (aged Ͻ1 y, chest irradiation, exposed to any anthracycline). † 0% discount. ‡ Nondominated strategies are screening frequencies that are neither less effective nor more expensive than Ն1 competing alternative. § Discrepancies may exist because of rounding.
As recommended by the COG guidelines for each risk profile. The row values for the entire anthracycline-exposed cohort are weighted means of the values across the 11 risk profiles, with percentages of the risk profiles in the cohort used as weights. The ICER was calculated by dividing the weighted mean of the cost over the 11 risk profiles by the weighted mean of the QALY over the 11 risk profiles. ¶ Shown are the incremental QALYs and ICERs, compared with no screening, for the entire anthracycline-exposed cohort based on screening frequency in each risk profile with an ICER less than $100 000 per QALY when compared with the immediately preceding less expensive nondominated strategy for that risk profile (bold and italicized rows, except for risk profiles 5 and 10, as explained in the next footnote). **For risk profile 5, the screening frequency with an ICER less than $100 000 is the same as that of the COG guidelines. For risk profile 10, the corresponding screening frequency is 10 y (incremental QALY, 0.017; ICER, $93 400; results not shown).
† † Nonitalicized bold rows correspond to screening frequencies recommended by the COG guidelines. ‡ ‡ The frequency was removed because of extended dominance (i.e., the frequency gained fewer QALYs and was more costly than Ն1 other alternative frequency).
Original Research Cost-Effectiveness of Children's Oncology Group Echocardiographic Screening Guidelines 15.6%, respectively. The ICER for the cohort (compared with no screening) was $61 500 ( Table 3) . For risk profiles 2 to 12, the ICER ranged from $40 000 to $138 200 ( Table 3) . Within any age group, the ICER was better for patients at higher risk for HF because of chest irradiation or anthracycline dose, whether controlled for screening frequency or based on the frequencies in the COG guidelines.
Screening Frequencies of 1 to 5 Years
The base-case analyses examined the frequencies recommended by the COG guidelines; however, these screening frequencies may not be optimal. Our results indicate that the costliest-but most effective-strategy was annual screening (ICER, $43 100 to $368 400), and the least expensive was screening every 5 years (ICER, $18 300 to $138 200). Given these observations, we identified the most cost-effective screening frequencies costing less than $100 000 per QALY. Under this constraint (Table 3) , annual screening recommendations in the COG guidelines were reduced to every 2 to 4 years depending on the risk group, and biennial screening was reduced to every 5 years; screening every 5 years, recommended for risk profiles 5 and 10, was maintained for the former and reduced to every 10 years for the latter. This overall less frequent screening strategy maintained 80% of the health benefits of the COG guidelines at nearly half the ICER ($33 200, relative to no screening): Life expectancy gain was 4.9 months (vs. 6.1 months), QALY gain was 0.11 (vs. 0.13), and the reduction in HF risk at 30 years after diagnosis was 14.3% (vs. 17.5%). When compared with the overall less frequent screening strategy, the COG guidelines had an overall ICER of $185 300.
Sensitivity Analyses
The ICER was most sensitive to ALVD treatment efficacy (percentage reduction in annual HF incidence) (Figure) . If treatment efficacy was 50%, the ICER decreased to $34 900 (base case, $61 500) and the reduction in HF risk at 30 years after cancer diagnosis increased to 28.6% (base case, 17.5%). When treatment efficacy was 10%, the HF risk at 30 years decreased by 7.8% and the ICER was $167 200. Limiting the duration of treatment efficacy to 6 years, as observed in 1 study (4), increased the ICER ($118 100) and decreased the reduction in HF risk at 30 years after cancer diagnosis to 10.7%.
The ICER was next most sensitive to the cost of echocardiography. Doubling the cost increased the ICER ($97 700). When the echocardiographic sensitivity and specificity were 50%, screening was more costly (ICER, $99 600) but the effect on reducing the HF risk at 30 years was small (16.2% vs. 17.5% for the base case). Complete adherence (100%) to ALVD treatment improved costeffectiveness (ICER, $46 600) and resulted in a larger reduction (22.2%) in HF risk at 30 years after diagnosis. Low adherence (50%) made screening more costly (ICER, $89 700) and decreased the percentage reduction in HF risk at 30 years (12.8%).
Screening was more cost-effective (ICER, $47 000) if HF utilities (quality-of-life weight) were lower than assumed for the base case and was less cost-effective (ICER, $82 500) if they were higher. The ICER was least sensitive to changes in HF risk at 20 years after cancer diagnosis: $44 500 and $53 800, respectively, for a 20% higher and a 20% lower risk. The ICERs for 0% and 5% discount rates were $44 500 and $78 900, respectively. Two-way sensitivity analyses (Appendix Figure 5 , available at www.annals.org) showed that the ICER of the guidelines remained below $100 000 if ALVD treatment efficacy was 20% or higher and the echocardiographic sensitivity and specificity were at least 75% and 90%, respec- tively. If treatment efficacy was 10% or less, the ICER would exceed $142 000 even with 100% echocardiographic sensitivity and specificity.
DISCUSSION
Echocardiographic screening for ALVD by following the COG guidelines, with subsequent treatment, could extend the life expectancy of a childhood cancer survivor by 6.1 months, increase QALYs by 1.6 months, and reduce the HF risk at 30 years after cancer diagnosis by 18%. The cost per QALY gained (compared with no screening) was $61 500, which is lower than the $100 000 per QALY often cited to assess the cost-effectiveness of interventions (a QALY is 1 year of life lived in perfect health, reflecting the quantity and quality of life) (44) . We also identified a more cost-effective screening strategy ($33 200 per QALY) that calls for less frequent screening than the COG guidelines while preserving most of the health benefits.
If $100 000 were used as the cost-effectiveness benchmark, the COG guidelines would not be considered costeffective for ALVD treatment efficacy of 10% or less or for treatment efficacy that was short-lived (for example, 6 years, as suggested by 1 study [4] ) if other variables were fixed. However, the cost per QALY remained around HF ϭ heart failure; ICER ϭ incremental cost-effectiveness ratio; QALY ϭ quality-adjusted life-year.
Original Research Cost-Effectiveness of Children's Oncology Group Echocardiographic Screening Guidelines $100 000 or less for echocardiographic sensitivity and specificity as low as 50%, doubling of echocardiography cost, treatment adherence of 50% (equivalent to 15% ALVD treatment efficacy), and HF quality of life that was higher or HF risk at 20 years after cancer diagnosis that was lower than that assumed for the base case. Two-way sensitivity analyses further showed that the cost per QALY of screening was around $100 000 or less if ALVD treatment efficacy was 30% or higher even for low echocardiographic sensitivity and specificity of 50%. For a lower ALVD treatment efficacy of 20%, the cost per QALY remained under $100 000 as long as the echocardiographic sensitivity and specificity were higher than 75% and 90%, respectively. Heidenreich and colleagues (19) examined the costeffectiveness of a 1-time screen for ALVD that used serum B-type natriuretic peptide and echocardiography (92% sensitivity and 96% specificity) in older adults in the general population. The efficacy of ACE inhibitor therapy for ALVD was assumed to be 34%. They estimated the cost per QALY of echocardiography as $69 000 (2010 U.S. dollars) compared with no screening. It is difficult to compare their results with ours given the differences in at-risk population (older, general population vs. anthracyclineexposed childhood cancer survivors), screening frequency (1-time vs. repeated), and confirmation diagnostics (none vs. cardiac MRI). Nevertheless, both studies suggest that echocardiographic screening for ALVD is cost-effective. We found screening to be more cost-effective for survivors exposed to higher anthracycline doses, with an attendant higher risk for anthracycline-related HF. Heidenreich and colleagues also showed that cost-effectiveness of screening with B-type natriuretic peptide increased as ALVD prevalence increased. Other programs for preventing HF also found screening to be more beneficial for populations with higher risks (45, 46) .
Reductions in HF risk were greater soon after cancer diagnosis, possibly because at younger ages the HF risk is higher than the competing risks for non-HF death. The burden of chronic diseases (and the attendant mortality) in this cohort increases with time since cancer diagnosis (47, 48), which we addressed by the multiplicative risk assumption. The benefit of screening for 1 disease (ALVD) is mitigated with time because the rate of non-HF-related mortality increases. Therefore, beginning screening soon after cancer diagnosis could better control HF risk.
Our assessment of the cost-effectiveness of the COG guidelines is limited by 2 sources of uncertainty: first, assumptions derived largely from adult data on ALVD treatment efficacy, the sensitivity and specificity of echocardiography, and medication adherence; second, assumptions of constant HF risk beyond 20 years after cancer diagnosis and use of a multiplicative risk model to estimate non-HF mortality at older ages.
The implications of the first source of uncertainty can be gleaned from the results of sensitivity analyses: The COG guidelines would not be cost-effective if the true ALVD treatment efficacy in childhood cancer survivors were lower than 20% and the sensitivity and specificity of echocardiography were lower than 75% and 90%, respectively, or if treatment efficacy (at 30%) is limited to 6 years or medication adherence was lower than 50%. However, the treatment efficacy for therapies combining ACE inhibitors and ␤-blockers, as well as the duration of treatment efficacy, is currently unknown and merits future investigation.
The second source of uncertainty (holding HF risk constant beyond 20 years and assuming a multiplicative model for excess non-HF mortality) underestimates the lifetime risk for HF and, therefore, the cost-effectiveness of screening. In fact, when we applied the additive risk assumption in 1 risk profile setting, the estimated cost per QALY was lower than that of the multiplicative risk assumption, showing that the multiplicative model we used tends to underestimate the cost-effectiveness of screening. Finally, we did not address the cost of heart transplantation, which also may underestimate the cost-effectiveness of screening.
Strengths of our study include simulating the entire cohort of anthracycline-exposed childhood cancer survivors and their characteristics, which made our assessment of the cost-effectiveness of screening more realistic than if a narrow subgroup of individuals were examined. We also identified optimal screening frequencies for individual risk profiles, hence a more cost-effective screening strategy for the cohort.
In summary, lifetime echocardiographic screening for ALVD as recommended by the COG guidelines would be cost-effective for decreasing the HF risk in anthracyclineexposed childhood cancer survivors, given that ALVD treatment efficacy exceeds 20%. A more cost-effective strategy involving less frequent screening, and hence less patient burden, could provide similar health benefits at half of the cost. On the basis of our modeling using the CCSS cohort, annual screening recommended by the guidelines for more than 50% of survivors could be decreased to every 2 to 4 years. The biennial screening recommended for more than 30% of survivors may be decreased to every 5 years. Screening every 5 years, recommended for 3% of survivors, could be maintained, but the frequency could be reduced to 10 years for an additional 12% of the survivors. This study provides a rationale for decreasing the screening frequencies in the COG guidelines.
with ALVD (12). The annual percentage reduction in the rate of progression to symptomatic disease was estimated to be 34% (19); post hoc examination of the SOLVD data found that 24% of mostly asymptomatic patients were receiving a ␤-blocker in addition to an ACE inhibitor (49) . A recent study evaluating the efficacy of a combination of ACE inhibitor and ␤-blocker (enalapril and carvedilol) in adults with cancer and ALVD treated with anthracyclines showed a 30% annual reduction in progression to clinical HF (20) . Although the results of a double-blind controlled trial of an ACE inhibitor in long-term pediatric cancer survivors were inconclusive (35) , another study found benefit in terms of delaying heart disease progression (4) . Therefore, we assumed 30% as the efficacy of ALVD therapy to reduce the annual incidence of HF.
Incidence of HF
Nine studies (3, 21-28) of 7 anthracycline-exposed childhood cancer survivor cohorts were identified (sample size ranged from 115 to 4765; median, 424) that reported the risk factors for HF or the cumulative incidence of HF up to 30 years after anthracycline treatment. The reported cumulative incidence of HF included the following: 10% at 15 years (24); 2.5% at 7 years and 5.5% at 20 years (22); between 10% and 18% at 20 years, depending on the dose of chest irradiation (25) ; 4% at 30 years (21); and 12.6% at 30 years for both anthracycline-and radiation-exposed survivors (24). Independent risk factors reported for HF included cumulative anthracycline dose (3, (21) (22) (23) (24) (25) (26) (27) (28) , chest irradiation (21, 23-25, 27, 28) , female sex (21, 26) , and younger age at cancer treatment (3, 21, 24, 26) . These risk factors inform the risk profiles of the COG guidelines (Appendix Table 1 ).
Our overall strategy for estimating the annual incidence of HF for the anthracycline-exposed childhood cancer survivor cohort by time since cancer diagnosis began by defining 5 dose categories of anthracycline: 1 to 249, 250 to 349, 350 to 449, 450 to 549, and at least 550 mg/m 2 . For the lowest dose category, we used the estimates of the cumulative incidence of HF at 10, 15, 20, 25, and 30 years after cancer diagnosis reported in a CCSS study (21) . The relative risks for HF for higher dose categories relative to the lowest were estimated from published studies, which were used to calculate the cumulative incidences of HF for the higher dose categories. These processes provided the cumulative incidence of HF by time since cancer diagnosis and anthracycline dose categories for the anthracycline-exposed childhood cancer survivor cohort, but without including the effects of age at cancer diagnosis, chest irradiation, and sex.
To estimate the cumulative incidence of HF by time since cancer diagnosis stratified by age at cancer diagnosis, chest irradiation, and sex, we sought estimates of the relative risk for these risk factors from the literature (described in the following paragraphs). Using the relative risk estimates thus obtained and the percentages of the CCSS participants in the strata defined by the risk factors and dose categories, we calculated the cumulative incidence of HF by time since diagnosis for the lowest-risk group (that is, males without chest irradiation diagnosed with cancer at age Ն5 years). The relative risks for the risk factors were then used to calculate the cumulative incidence of HF for the remaining risk groups as a function of the cumulative incidences in the lowest-risk group. Annual HF incidence rates between 5-year intervals were then calculated by linear interpolation. Cubic polynomials were fitted to smooth the incidence functions. Linear extrapolation was used to obtain values between 5 and 10 years. Given the paucity of data, we fixed the rates beyond 20 years since cancer diagnosis at the 20-year rate while incorporating the age-and sex-specific HF incidence rate of the general population, which were estimated from the 2001 National Hospital Discharge Survey (29) and data from the 2000 U.S. Census (Appendix Figures 2 and 3) .
Relative Risks for HF Risk Factors
The relative risks for anthracycline dose categories of 250 to 349, 350 to 449, 450 to 549, and at least 550 mg/m 2 relative to 1 to 249 mg/m 2 at 30 years after cancer diagnosis were estimated to be 3, 5, 6, and 7 (23) after the reported relative risks at the 3 highest dose categories were decreased by 70%, 40%, and 20%, respectively, to account for the greater uncertainty there. We used relative risks of 2, 3, 4, and 5 at 10 years after cancer diagnosis for the respective increasing dose categories, thus allowing for smaller differences in risks by anthracycline dose observed in the earlier follow-up period (21, 24) . The relative risks at 15, 20, and 25 years were adjusted so that the cumulative incidence increased smoothly.
The relative risks of chest irradiation at 20, 25, and 30 years since cancer diagnosis (1.6, 2.0, and 2.0, respectively) were estimated from a CCSS analysis (28) . To allow for smaller relative risk seen earlier in the follow-up (26), we used relative risks of 1, 1.2, 1.5, 1.7, and 2.2 at 10, 15, 20, 25, and 30 years since cancer diagnosis.
The relative hazard for females was estimated to be 1.4 (21, 27) . Because the female-male risk increased with the cumulative anthracycline dose up to 500 mg/m 2 , with the difference attenuating slightly beyond that dose (26), we assumed the relative risk for females to be 1.05, 1.2, 1.8, 1.6, and 1.6 at anthracycline doses of 200, 300, 400, 500, and greater than 500 mg/m 2 , respectively.
The studies that examined the effects of age at diagnosis showed inconsistent results. Nevertheless, to incorporate age effects, we chose the lowest relative risk estimate of 1.5 reported for age younger than 4 years versus age 4 years or older (3) from among the studies that reported significant effects of age at cancer diagnosis (3, 21, 24) and applied it as the relative risk for HF for age at cancer diagnosis less than 5 years versus 5 years or older.
Incidence of ALVD
We found no studies reporting the annual incidence of ALVD in anthracycline-exposed survivors of childhood cancer. However, a systematic review (50) identified 25 studies conducted between 1966 and 2001, each with more than 50 children, that reported the frequencies of subclinical cardiotoxicity. The validity of the studies was rated from 0 (worst) to 8 (best). A similar systematic review (51) identified 30 studies reporting the incidence of anthracycline-induced HF in children. Their validity scores ranged from 0 to 5. The median ALVD prevalence re-ported among 17 studies with validity scores of 2 or higher was 13.3% (range, 2.6% to 39.2%); among 16 studies with validity scores of 3 or higher, the prevalence was 14.2% (range, 2.6% to 39.2%). The median of HF incidences was 4.2% (range, 0.8% to 10.5%) among 21 studies with validity scores of 2 or higher and 4.7% (range, 0.8% to 10.5%) among 13 studies with validity scores of 3 or higher. Computing the incident ALVD-HF ratio by using all 4 combinations of the medians gives ALVD-HF ratios of 2.8, 3.0, 3.2, and 3.4, suggesting an incident ALVD-HF ratio of 3. A prospective cohort study (52) of 265 anthracycline-exposed patients with childhood sarcoma estimated the cumulative incidence of ALVD and HF to be 6% and 1.5%, respectively, at a mean follow-up of 2.8 years, suggesting a 4-fold greater risk for incident ALVD to incident HF. A more recent systematic review identified 18 studies of cardiotoxicity in adult and childhood cancer survivors exposed to anthracycline that had more than 200 patients and were conducted between 1979 and 2011 (53) . Using meta-analyses, the authors estimated the incidence of clinically overt cardiotoxicity as 6% (95% CI, 3% to 9%) and the incidence of subclinical cardiotoxicity as 18% (CI, 12% to 24%) after a median follow-up of 9 years, thus providing further support for an incident ALVD-HF ratio of 3. Therefore, we assumed the incidence of ALVD to be 3 times the incidence of HF for all risk groups in our simulations.
Incidence of HF After ALVD
Because the incidence of HF for patients with ALVD should be greater than the incidence of HF that considers the entire anthracycline-exposed childhood cancer survivor cohort, which includes survivors with and without ALVD, the incidence of HF for those with ALVD (that is, HF incidence conditional on ALVD) was obtained by inflating the cohort HF incidence rate using an HF multiplier. The multiplier values were determined by calibration while the Markov-state simulation was performed under the no-screening condition. The HF multiplier was adjusted as necessary so that the cumulative incidence of HF at 20 years after cancer diagnosis in the simulated cohort, with death taken into account as a competing risk (54) , attained the values assumed (to the second significant digit) based on the synthesized model for HF incidence. This process was carried out for each risk profile by using a random sample of 100 000 individuals.
Annual Mortality Rate From Causes Other Than HF
Poisson regression was performed by using the AMFIT module of the EPICURE package of programs (55) with use of the CCSS data (627 non-HF deaths) to estimate non-HF mortality as a function of sex, age at diagnosis (Ͻ1 year, 1 to 4 years, and Ն5 years), chest irradiation status (yes or no), cumulative anthracycline dose, attained age, and year of cancer diagnosis (before 1974, 1974 through 1977, 1978 through 1981, and 1982 through 1986 Each term in brackets equals 1 if true or 0 if false, except for attained age and anthracycline dose, which are integers. Sex, chest irradiation, age at diagnosis, and anthracycline dose (all P Ͻ 0.001) were included in the model to be consistent with the COG guidelines risk profiles. Because the quadratic effect of anthracycline dose was nonsignificant (P ϭ 0.084), only the linear term was retained (P ϭ 0.015 [CI, 0.000065 to 0.00081]). The age-squared term (P Ͻ 0.001) was included because of biological plausibility. Year-of-diagnosis categories (P Ͻ 0.001) were included to account for temporal variation in mortality. Model fit was satisfactory according to the likelihood ratio test calculated from deviance residuals (55) when compared with the model without the predictors (likelihood ratio statistics ϭ 350.4; P Ͻ 0.001).
Because of limited follow-up data in the CCSS, the estimated non-HF mortality was considered to be reliable up to age 30 years for survivors diagnosed with cancer before age 5 years and up to age 40 years for those diagnosed at age 5 years or older. Non-HF mortality rates beyond these ages were estimated by assuming the multiplicative model for excess non-HF death by using relative risks estimated at ages 30 and 40 years compared with the age-and sex-specific U.S. general population rates (the average of the 5 quinquennial census reports from 1980 to 2000) (Appendix Figure 4) .
Utilities
We used the utilities for the 4 classes of HF defined in the New York Heart Association classification that were estimated from 64 healthy men and women by using the time-tradeoff method (34) . The mean utility scores reported for classes III and IV (which closely correspond to stages C and D of the American Heart Association/American College of Cardiology definition of HF) were averaged to be used for our HF health state, which combined stages C and D.
In the randomized clinical trial of an ACE inhibitor (enalapril) in pediatric patients with cancer exposed to anthracycline (35) , dizziness or hypotension was observed in 22% of patients in the ACE inhibitor group compared with 3% in the placebo group. The only clinical trial to randomly assign adults with ALVD to an ACE inhibitor versus an ACE inhibitor plus a ␤-blocker found no difference in prevalence or severity of reported symptoms of adverse events between the groups (56). We thus assumed that 20% of patients receiving ALVD treatment would experience dizziness from the medication. The decrement in utilities for these patients was increased by 25% relative to the utilities of the no-ALVD health state on the basis of a study of 52 patients with benign paroxysmal positional vertigo whose utili-ties, measured by the time-tradeoff method, improved by 25% after treatment compared with before (36) .
Costs
Patients who tested positive for ALVD on echocardiographic screening underwent cardiac MRI for confirmation. A negative echocardiogram prompted no further testing until the next screening cycle. Echocardiography and cardiac MRI costs were based on CPT (Current Procedural Terminology) codes (CPT 93306 and 99205 for first-time screening with echocardiography and CPT 93306 and 99214 for all subsequent screening; CPT 75561 and 99205 for first-time screening with cardiac MRI; and CPT 75561 and 99214, for all subsequent screening).
The costs of general health care (40) and hospitalization for HF and non-HF were age-dependent. Hospitalization costs for HF were obtained from the Healthcare Cost and Utilization Project (41) 
APPENDIX 2: RESULTS
Model Validation
The external validity of the model was assessed by comparing the cumulative incidence of HF estimated at 20 years after cancer diagnosis against the estimates reported in 4 large cohort studies of anthracycline-exposed childhood cancer survivors comprising more than 500 patients (21) (22) (23) 28) . Because these studies reported only aggregated patient characteristics, it was not possible to determine the relative frequencies of patient characteristics that corresponded to the specific risk profiles in the COG guidelines for calculating the corresponding model-based cumulative incidences. Therefore, we identified all risk profiles in the guidelines for which patient characteristics are consistent with the 4 studies and present the corresponding ranges of cumulative incidence of HF output in our simulation. Our estimates at 20 years are similar to the point estimates or fall within the 95% confidence bounds reported by these longitudinal studies (Appendix Table 3 ).
The face validity of the model results was assessed by having our expert clinicians compare the following outputs across screening frequencies within each risk profile, across levels of risk factors within each risk profile, and across risk profiles: computed costs, QALYs, life expectancy, mean age at onset of ALVD and HF, the number of cases of ALVD and HF, the number of HF cases prevented, the duration of the preclinical stage of disease during which it can be detected by screening (that is, the disease sojourn time), and the cumulative incidence of HF. The distributions of the age of onset of ALVD and HF were also examined and compared by risk profiles for face validity. The cumulative incidence rates of HF at 20 years after cancer diagnosis that were estimated from the simulated data were verified against the values assumed in our modeling. HF ϭ heart failure. HF ϭ heart failure; RR ϭ relative risk (compared with the U.S. population).
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